{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:37:52Z","timestamp":1775687872821,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Brentuximab vedotin (BV) is a potent therapeutic option for CD30\u2010positive cutaneous T\u2010cell lymphoma. Unlike existing studies, BV and other therapeutic procedures were frequently combined for our patients. In this context, the study aims to analyze the effectiveness and safety of BV in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>This is a retrospective monocentric study analyzing treatment outcomes for patients with CD30\u2010positive cutaneous T\u2010cell lymphoma treated with BV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>26 patients (median age: 67 years) were included in the study. Patients were treated with 1.8 or 1.2\u00a0mg\/kg b.w. Complete remission (CR) was reached in 30.8\u00a0% of the patients, and the objective response rate (ORR) was 84.6\u00a0%. Side effects were seen in 19 of the 26 patients. As a reaction to progressive disease (PD) under BV monotherapy, we included skin\u2010directed procedures such as tumor excision, local radiotherapy, and PUVA for six patients. We re\u2010stabilized the disease and maintained the line of therapy without additional toxicities for a median of seven months longer using this concept.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Addition of skin\u2010directed therapies (SDT) after disease progression under BV monotherapy could stabilize the disease\u2019s continuous advancement or even lead to partial response, thereby extending the time until the next therapeutic escalation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.14342","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T14:51:06Z","timestamp":1614005466000},"page":"383-387","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Combination of brentuximab\u2010vedotin with skin\u2010directed therapies extends the time to the next therapeutic line in patients with cutaneous T\u2010cell lymphoma"],"prefix":"10.1111","volume":"19","author":[{"given":"Ren\u00e9","family":"Stranzenbach","sequence":"first","affiliation":[{"name":"Department of Dermatology Venerology Allergology and Phlebology Johannes Wesling Medical Centre University Hospital of Ruhr\u2010University Bochum  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venerology Allergology and Phlebology Johannes Wesling Medical Centre University Hospital of Ruhr\u2010University Bochum  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.06.008"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2289"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15801"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0488"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.13.4307"},{"key":"e_1_2_6_8_1","unstructured":"National Center for Biotechnology Information.TNFRSF8 TNF receptor superfamily member 8 [Homo sapiens (human)]Available from:http:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=943[Last accessed February 18 2016]."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-011-0096-8"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351346"},{"key":"e_1_2_6_11_1","unstructured":"European Medicines Agency.Assessment report: Adcetris. 2017. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/variation\u2010report\/adcetris\u2010h\u2010c\u2010002455\u2010ii\u20100048\u2010epar\u2010assessment\u2010report\u2010variation_en.pdf(Last accessed February 18 2019)."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"e_1_2_6_13_1","first-page":"112","article-title":"S2k Guidelines \u2013 Cutaneous Lymphomas Update 2016 \u2013 Part 2: Treatment and Follow\u2010up (ICD10 C82 \u2010 C86)","volume":"16","author":"Dippel E","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17240"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.027"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14342","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.14342","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:28:41Z","timestamp":1693549721000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.14342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/ddg.14342"],"URL":"https:\/\/doi.org\/10.1111\/ddg.14342","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"assertion":[{"value":"2020-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}